(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 October 2020 (08.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/204765 A1

(51) International Patent Classification:

A61K 39/395 (2006.01)	*A61P 19/02* (2006.01)
A61K 9/08 (2006.01)	*A61P 1/00* (2006.01)
A61K 47/18 (2017.01)	*A61P 11/06* (2006.01)
A61K 47/26 (2006.01)	*A61P 37/08* (2006.01)
A61K 47/12 (2006.01)	*A61P 17/06* (2006.01)

(21) International Application Number:
PCT/RU2020/050065

(22) International Filing Date:
02 April 2020 (02.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2019109641 02 April 2019 (02.04.2019) RU

(71) Applicant: **JOINT STOCK COMPANY "BIOCAD"** [RU/RU]; Liter A, bld. 34, Svyazi st., Strelna, Petrodvortsoviy district, Saint Petersburg, 198515 (RU).

(72) Inventors: **CHERNIAEVA, Ekaterina Valerevna**; ul. Profsoyuznaya, d.152, korp. 4, kv. 96, Moscow, 117321 (RU). **LOMKOVA, Ekaterina Aleksandrovna**; pr-kt Moskovskij, 216, kv. 19, Saint Petersburg, 196066 (RU). **ARTEMEVA, Antonina Vasilevna**; ul. Ziny Portnovoj d.11 kv. 103, Saint-Petersburg, 198207 (RU). **EREMEEVA, Anna Viktorovna**; Dunajskij pr. d. 48, korp 1, kv. 243, Saint-Petersburg, 192284 (RU). **IVANOV, Roman Alekseevich**; ul. Planetnaya, 29, korp. 2, kv. 176, Moscow, 125167 (RU). **RYAKHOVSKAYA, Anastasiya Mikhajlovna**; ul. Zaytseva, d. 19/18A, kv. 41, Saint-Petersburg, 198188 (RU). **SHITIKOVA, Viktoriia Olegovna**; ul. Kazanskaya (Malaya Okhta), d.18, kv. 81, Saint-Petersburg, 195213 (RU). **IAKOVLEV, Aleksandr Olegovich**; ul. Donetskaya, d. 26, kv. 9, Moscow, 109651 (RU). **MOROZOV, Dmitry Valentinovich**; Admiraltejskij r-n, ul. Pochtamtskaja, d. 20, kv. 3, Saint Petersburg, 190000 (RU).

(74) Agent: **POLUDNICYNA, Galina Vladimirovna**; Liter A, bld. 34, Svyazi st., Strelna, Petrodvortsoviy district, JSC "BIOCAD", Saint Petersburg, 198515 (RU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the identity of the inventor (Rule 4.17(i))*
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: AQUEOUS PHARMACEUTICAL COMPOSITION OF AN ANTI-IL17A ANTIBODY AND USE THEREOF

(57) Abstract: The present disclosure relates to aqueous compositions for anti-IL17a antibodies, and more particularly to aqueous compositions for anti-IL17a antibodies with a V_{HH} variable domain and a V_L variable domain, and can be used as a medicinal agent for treating IL-17A-mediated diseases.

WO 2020/204765 A1